Tussilago Farfara

Dosage for Tussilago Farfara allergenic extract is highly individualized and is never a 'one-size-fits-all' approach.

• For Diagnostic Testing: A single drop of the extract (typically 1:10 or 1:20 concentration) is applied to the skin, followed by a prick or scratch. If an intradermal test is required, 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 100 PNU/mL or a 1:1000 dilution) is injected.
• For Immunotherapy: Treatment begins with a 'build-up phase.' The starting dose is usually 0.1 mL of a very low concentration (e.g., 1:100,000 w/v). Doses are increased weekly or bi-weekly by 0.1 mL to 0.5 mL until a 'maintenance dose' is reached. The maintenance dose is typically 0.5 mL of a 1:100 or 1:10 concentration, depending on patient tolerance.

Pediatric dosing follows the same principles as adult dosing, with adjustments based on the child's sensitivity rather than weight. However, immunotherapy is generally not recommended for children under the age of 5 due to the difficulty of communicating early symptoms of systemic reactions. Healthcare providers must weigh the benefits against the risks of anaphylaxis in younger children.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through the kidneys in a manner that would lead to systemic accumulation. However, patients with severe renal disease may have altered skin reactivity.

Hepatic Impairment

No dosage adjustments are typically necessary for hepatic impairment. However, if the patient is using herbal forms of Tussilago Farfara (which contain hepatotoxic pyrrolizidine alkaloids), the presence of liver disease is a major contraindication for the herbal form, though it does not strictly affect the allergenic extract used in allergy clinics.

Elderly Patients

Elderly patients may have reduced skin reactivity, leading to potential false negatives in diagnostic testing. Furthermore, the risk of cardiac complications during a systemic reaction (anaphylaxis) is higher in this population, necessitating cautious dosing.

Tussilago Farfara allergenic extract is administered exclusively by healthcare professionals in a clinical setting.

• Skin Testing: The skin (usually the forearm or back) is cleaned with alcohol. The extract is applied, and the skin is pricked. Results are read exactly 15 to 20 minutes later.
• Immunotherapy: The injection is given subcutaneously in the upper arm. The site should not be massaged after injection. Patients must remain in the clinic for at least 30 minutes post-injection to monitor for signs of a systemic reaction.
• Storage: Extracts must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). They should never be frozen.

In immunotherapy, consistency is critical. If a dose is missed:

• Less than 1 week late: The usual dose may be given.
• 1 to 2 weeks late: The dose may need to be reduced to the previous level.
• More than 3 weeks late: The dose may need to be significantly reduced, or the build-up phase may need to be restarted. Consult your allergist immediately if you miss an appointment.

An 'overdose' in the context of allergenic extracts refers to a dose that exceeds the patient's current threshold of tolerance, potentially triggering a systemic allergic reaction or anaphylaxis.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, or a sudden drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by oxygen, IV fluids, and antihistamines. Emergency medical services must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-administer these extracts without medical guidance.

Most patients undergoing skin testing or immunotherapy with Tussilago Farfara will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Erythema: Redness at the site of injection or testing. This usually appears within minutes and fades within a few hours.
• Pruritus (Itching): A localized itching sensation at the site of contact. This is a direct result of histamine release in the skin.
• Wheal Formation: A raised, white or pale red bump at the test site. In immunotherapy, a local swelling larger than a quarter (2.5 cm) should be reported to the doctor as it may indicate the need for a dose adjustment.

• Delayed Local Reactions: Swelling and redness that appear 6 to 24 hours after administration. These can be treated with cold compresses or topical corticosteroids.
• Fatigue: Some patients report feeling unusually tired for several hours after an immunotherapy injection.
• Mild Rhinorrhea: A slightly runny nose or sneezing shortly after treatment, indicating a mild systemic immune activation.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Laryngeal Edema: Swelling of the throat that can cause difficulty swallowing or speaking.
• Syncope: Fainting or lightheadedness, which may be a vasovagal response or a sign of early anaphylaxis.

> Warning: Stop taking Tussilago Farfara treatments and call your doctor or emergency services immediately if you experience any of these symptoms of anaphylaxis:

• Difficulty Breathing: Wheezing, chest tightness, or a persistent cough.
• Swelling: Significant swelling of the tongue, lips, or throat.
• Cardiovascular Collapse: A sudden drop in blood pressure, feeling faint, or turning pale/blue.
• Rapid/Weak Pulse: Tachycardia (fast heart rate) coupled with a sense of 'impending doom.'
• Nausea and Vomiting: Sudden gastrointestinal distress following an injection is often an early sign of a systemic reaction.

In the context of the plant itself (if ingested orally as a supplement), Tussilago Farfara contains pyrrolizidine alkaloids (PAs) such as senkirkine. Long-term exposure to these alkaloids is associated with:

• Hepatotoxicity: Specifically, hepatic veno-occlusive disease (HVOD), where the small veins in the liver become obstructed.
• Carcinogenicity: Animal studies have suggested that high doses of PAs found in Tussilago Farfara may increase the risk of liver tumors.

Note: These risks are primarily associated with oral ingestion of the herb, not the controlled use of purified allergenic extracts for skin testing.

While Tussilago Farfara specifically may not have a unique black box warning, the entire class of allergenic extracts carries a standard FDA-mandated warning regarding anaphylaxis:

WARNING: RISK OF SEVERE ALLERGIC REACTION

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• Do not administer if the patient has severe, unstable, or steroid-dependent asthma.
• Patients must be observed for at least 30 minutes in a facility equipped to treat anaphylaxis.
• Certain medications (like beta-blockers) may make a patient unresponsive to epinephrine, the standard treatment for anaphylaxis.

Report any unusual symptoms to your healthcare provider immediately.

Tussilago Farfara allergenic extract must only be used by clinicians who are experts in allergy and immunology. The most critical safety concern is the potential for a systemic allergic reaction. Patients should be in stable health on the day of their injection; if you have a fever, respiratory infection, or an asthma flare-up, your appointment should be rescheduled.

No specific FDA black box warning exists for Tussilago Farfara individually; however, it falls under the general warning for all Non-Standardized Allergenic Extracts. This warning emphasizes that these products can cause anaphylaxis and should only be administered by trained personnel. It also notes that the potency of non-standardized extracts can vary between lots, requiring careful clinical monitoring during a change in vials.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. The risk is highest during the build-up phase of immunotherapy or when starting a new vial of extract.
• Asthma Status: Patients with uncontrolled asthma are at a significantly higher risk for a fatal reaction to allergenic extracts. Asthma must be well-controlled (e.g., FEV1 > 70% of predicted) before administration.
• Hepatotoxicity (Herbal Context): If using Tussilago Farfara as a traditional tea or supplement, be aware that it contains senkirkine and senecionine. These are pyrrolizidine alkaloids that cause liver damage. The FDA has previously issued warnings regarding the internal use of plants containing these alkaloids.
• Cardiovascular Disease: Patients with pre-existing heart conditions may not tolerate the stress of a systemic reaction or the effects of epinephrine used to treat such a reaction.

• Observation Period: A mandatory 30-minute wait in the doctor's office after every injection.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before the injection to ensure lung function is stable.
• Liver Function Tests (LFTs): Only necessary if a patient has been chronically ingesting the herbal form of Tussilago Farfara, to screen for hepatotoxicity.

Generally, Tussilago Farfara does not affect the ability to drive. However, if a patient experiences a systemic reaction, lightheadedness, or receives antihistamines/epinephrine during a reaction, they should not drive until fully recovered and cleared by a physician.

Alcohol should be avoided on the day of an immunotherapy injection. Alcohol can increase blood flow to the skin and potentially accelerate the absorption of the allergen, increasing the risk of a systemic reaction. It can also mask the early symptoms of anaphylaxis.

If immunotherapy is discontinued for a period of several weeks, it cannot be resumed at the previous dose. The immune system's tolerance may have waned, and the dose must be tapered back significantly to ensure safety. Always consult your allergist before resuming treatment after a break.

> Important: Discuss all your medical conditions with your healthcare provider before starting Tussilago Farfara.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are strictly contraindicated for patients receiving Tussilago Farfara immunotherapy. Beta-blockers can make a patient resistant to the effects of epinephrine. If a patient on a beta-blocker has an anaphylactic reaction, the standard treatment (epinephrine) may fail, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of systemic reactions or worsen the severity of hypotension (low blood pressure) during an allergic event.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the metabolism of epinephrine, potentially leading to a hypertensive crisis if epinephrine is administered for an allergic reaction.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can potentiate the effects of epinephrine on the cardiovascular system.

• Antihistamines (e.g., Loratadine, Cetirizine): These medications will suppress the 'wheal and flare' response during diagnostic skin testing, leading to false-negative results. Antihistamines should be discontinued for 3 to 7 days prior to skin testing.
• H2 Blockers (e.g., Famotidine): These can also mildly suppress skin test reactivity and should be discontinued 48 hours before testing.
• Systemic Corticosteroids: Long-term use of oral steroids can suppress skin reactivity, though short-term use may not have a significant effect.

• High-Fat Meals: While not directly interacting with the extract, heavy meals and vigorous exercise immediately after an injection can increase systemic circulation and the risk of a reaction.
• Alcohol: As mentioned, alcohol can potentiate the allergic response and should be avoided for 24 hours around the time of treatment.

• Other Pyrrolizidine Alkaloid-containing Herbs (e.g., Comfrey, Borage): If the patient is using Tussilago Farfara as an allergenic extract while also consuming other PA-containing herbs, the risk of cumulative hepatotoxicity is significantly increased.
• St. John's Wort: May theoretically alter the immune response, though clinical data is limited.

Tussilago Farfara allergenic extract does not typically interfere with standard blood chemistries or hematology. However, it will directly affect:

• Skin Prick Tests: Causes a positive result in sensitized individuals.
• Serum Specific IgE (ImmunoCAP): Testing for Tussilago Farfara IgE will show elevated levels in allergic patients.

For each major interaction, the management strategy involves either discontinuing the interacting drug (like antihistamines before testing) or choosing alternative therapies (like switching from a beta-blocker to a calcium channel blocker before starting immunotherapy).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Tussilago Farfara allergenic extract must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted or those who have had a recent acute exacerbation are at an unacceptably high risk of fatal anaphylaxis.
• Beta-Blocker Therapy: As detailed previously, the inability to respond to epinephrine makes immunotherapy too dangerous.
• Previous Severe Reaction: If a patient has experienced a life-threatening reaction to Tussilago Farfara extract in the past, further use is generally contraindicated.
• Acute Infection: Administration during an active fever or respiratory infection increases the risk of a systemic reaction.

Conditions requiring a careful risk-benefit analysis include:

• Autoimmune Disorders: Immunotherapy may theoretically exacerbate conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis.
• Malignancy: Patients with active cancer may have altered immune systems that make the response to extracts unpredictable.
• Severe Cardiovascular Disease: The heart may not be able to withstand the stress of anaphylaxis or the treatment required for it.
• Pregnancy (Starting Treatment): It is generally recommended not to start immunotherapy during pregnancy due to the risk of anaphylaxis-induced uterine contractions.

Patients allergic to Tussilago Farfara often show cross-reactivity with other members of the Asteraceae (Compositae) family. This includes:

• Ragweed (Ambrosia)
• Dandelions (Taraxacum)
• Chamomile (Matricaria)
• Echinacea
• Sunflowers (Helianthus)

If you have a known severe allergy to any of these plants, your healthcare provider will exercise extreme caution when testing or treating you with Tussilago Farfara extract.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Tussilago Farfara.

Tussilago Farfara allergenic extract is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm.

• Risk Summary: The primary risk during pregnancy is not the extract itself, but the potential for a systemic allergic reaction (anaphylaxis) in the mother. Anaphylaxis can lead to maternal hypotension, which causes placental hypoperfusion and fetal hypoxia (lack of oxygen).
• Clinical Recommendation: It is generally advised not to initiate Tussilago Farfara immunotherapy during pregnancy. However, if a patient is already on a stable maintenance dose and is tolerating it well, the physician may choose to continue the treatment at that same dose (without increasing it) throughout the pregnancy.

It is not known whether the components of Tussilago Farfara allergenic extract are excreted in human milk. However, because the extract consists of large proteins that are processed locally or broken down into amino acids, it is highly unlikely that significant amounts would reach the infant through breast milk. The benefits of breastfeeding generally outweigh the theoretical risks, but the mother should be monitored for any unusual reactions.

• Approved Use: Allergenic extracts are used in children, but safety and efficacy for immunotherapy are best established in children aged 5 and older.
• Special Considerations: Children may have difficulty articulating the early symptoms of a systemic reaction (e.g., an itchy throat or a sense of 'weirdness'). Therefore, they require even closer observation by clinical staff.
• Growth Effects: There is no evidence that allergenic extracts interfere with normal growth and development in children.

• Sensitivity: Patients over 65 may have thinner skin and reduced mast cell density, which can lead to less reliable skin test results.
• Safety: The geriatric population is at higher risk for complications from anaphylaxis due to the higher prevalence of underlying cardiovascular disease.
• Polypharmacy: Elderly patients are more likely to be taking interacting medications like beta-blockers or ACE inhibitors, necessitating a thorough medication review.

There are no specific guidelines for Tussilago Farfara use in renal impairment. Since the proteins are degraded proteolytically, renal clearance of the parent compound is not a primary route of elimination. However, clinicians should be aware that uremia (high urea levels in the blood) can sometimes suppress skin test reactivity.

For the allergenic extract, no adjustments are needed. However, if the patient has pre-existing liver disease (such as cirrhosis or hepatitis), they must be strictly warned against using the herbal/tea form of Tussilago Farfara, as the pyrrolizidine alkaloids can cause further, potentially fatal, liver damage (veno-occlusive disease).

> Important: Special populations require individualized medical assessment.

Tussilago Farfara allergenic extract functions as an immunomodulator. In diagnostic use, it facilitates the Type I Hypersensitivity reaction. When the extract's proteins (allergens) encounter IgE antibodies on the surface of mast cells, they cause receptor cross-linking. This leads to an influx of calcium ions into the mast cell, resulting in the exocytosis of granules containing histamine, leukotrienes, and prostaglandins.

In therapeutic use (immunotherapy), the mechanism involves the induction of immune tolerance. Repeated exposure to increasing doses of Tussilago Farfara allergens leads to:

1. 1T-cell Anergy: Reduction in the responsiveness of allergen-specific Th2 cells.
2. 2Treg Induction: Increase in regulatory T-cells that produce IL-10.
3. 3Class Switching: B-cells switch from producing IgE to producing IgG4, which acts as a 'blocking antibody' to prevent future IgE-mediated mast cell activation.

• Onset of Action: For skin testing, the onset is rapid (15-20 minutes). For immunotherapy, clinical improvement in symptoms typically takes 3 to 6 months of consistent treatment.
• Duration of Effect: The diagnostic wheal-and-flare resolves within hours. The therapeutic effect of immunotherapy can last for several years even after the treatment is discontinued (usually after a 3-to-5-year course).
• Tolerance: Unlike many drugs, 'tolerance' here is the desired therapeutic goal—the body becoming 'tolerant' to the allergen.

| Parameter | Value |

|---|---|

| Bioavailability | Low (systemic); High (local interstitial) |

| Protein Binding | N/A (the drug itself is a protein) |

| Half-life | Minutes (proteins); Years (immunologic memory) |

| Tmax | 15-30 minutes (local reaction) |

| Metabolism | Proteolytic degradation by local proteases |

| Excretion | Renal (as small peptide fragments) |

• Composition: A complex mixture of water-soluble proteins, glycoproteins, and polysaccharides extracted from Tussilago Farfara.
• Active Components: Specific allergenic proteins (yet to be fully standardized) and trace amounts of plant secondary metabolites.
• Solubility: Highly soluble in buffered saline or glycerinated solutions.
• Storage: Must be kept at 2-8°C to prevent protein denaturation.

Tussilago Farfara belongs to the class of Non-Standardized Plant Allergenic Extracts. It is grouped with other botanical extracts like dandelion, sagebrush, and various tree pollens. It is distinct from 'Standardized Extracts' (like Ragweed or Grass), which have a federally mandated potency unit (e.g., BAU/mL).